BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19515014)

  • 1. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1075-126. PubMed ID: 20167001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
    Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
    Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
    J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.
    Hutzler JM; Balogh LM; Zientek M; Kumar V; Tracy TS
    Drug Metab Dispos; 2009 Jan; 37(1):59-65. PubMed ID: 18838506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
    Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
    J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
    Lai XS; Yang LP; Li XT; Liu JP; Zhou ZW; Zhou SF
    Curr Drug Metab; 2009 Nov; 10(9):1009-47. PubMed ID: 20214592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.
    Wang B; Zhou SF
    Curr Med Chem; 2009; 16(31):4066-218. PubMed ID: 19754423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
    Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
    Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
    Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
    Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
    Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
    Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
    Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
    Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor.
    Gerbal-Chaloin S; Daujat M; Pascussi JM; Pichard-Garcia L; Vilarem MJ; Maurel P
    J Biol Chem; 2002 Jan; 277(1):209-17. PubMed ID: 11679585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.